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Introduction 
The development of corticosteroids deliverable by 
inhalation represented a major step forward in the 
treatment of asthma. The optimal features of a corti- 
costeroid intended for inhalation are low water solu- 
bility (to maximize time spent in the lung), high 
receptor affinity (potency) and a short half-life in the 
systemic circulation (to minimize systemic adverse 
effects). This article will review the extent to which 
beclomethasone dipropionate (BDP) and budesonide 
meet these criteria. 
Structure-activity Relationships 
A Cl-C2 double bond in a corticosteroid molecule 
enhances glucocorticoid activity and reduces miner- 
alocorticoid activity. BDP is a 17a,21-diester with a 
chlorine atom in the 9a position (1). Budesonide is a 
16a, 17a-acetol-substituted molecule that does not 
contain a halogen atom. Budesonide is an equal mix- 
ture of two epimers designated 22R and 22s. The 
chemical structures of BDP and budesonide, and their 
primary metabolites, are provided in Figure 1. 
RECEPTOR AFFINITY 
Receptor affinity is a measure of how strongly the 
active molecule binds to the intracellular glucocorti- 
coid receptor, and it is related closely to the anti- 
inflammatory activity of the compound. High affinity 
of the compound for the glucocorticoid receptor will 
result in greater changes in the regulation of gene 
transcription and gene products, which will lead to 
modulation of inflammatory processes. When applied 
Correspondence should be addressed to: A. R. Boobis, 
Division of Medicine, Imperial College School of Medicine, 
Hammersmith Campus, London W12 ONN, U.K. 
This supplement was sponsored by Glaxo Wellcome plc. 
topically, budesonide demonstrates greater potency 
than BDP, based on the human skin vasoconstriction 
assay (2), with 22R-budesonide having 2-3 times the 
vasoconstricting potency of the 22s epimer (1). 
However, it has been recognized that this test may be 
unreliable for predicting clinical efficacy in the lungs. 
Indeed, although budesonide has 2-3 times better 
skin-blanching properties than BDP, numerous clini- 
cal studies in asthma treatment have shown that the 
two drugs have equivalent efficacy when administered 
at the same dose via the same type of delivery device. 
Rohdewald et al. (3) determined the receptor affini- 
ties of inhaled glucocorticoids by performing in vitro 
competition assays using human lung cytosol. Receptor 
affinities of the two drugs and the metabolites of BDP 
[expressed relative to dexamethasone (loo), with a high 
number indicating high affinity] are shown in Table 1. 
They found that BDP has a relative receptor affinity 20- 
fold less than that of budesonide. However, the relative 
receptor affinity of 17-beclomethasone monopropi- 
onate (17-BMP), one of the compounds to which BDP 
is transformed in the lung, is slightly greater (about 1.5 
times) than that of budesonide. This suggests that the 
metabolism of BDP to 17-BMP is actually an activa- 
tion step, rather than a deactivation step (as previously 
thought), and results in a compound with similar affin- 
ity to budesonide for the glucocorticoid receptor. 21- 
BMP has low affinity for the glucocorticoid receptor, as 
do the metabolites of budesonide. 
WATER SOLUBILITY 
Rohdewald et al. (3) also showed that BDP is poorly 
water soluble. The rate at which a compound dissolves 
in the aqueous mucous layer of the bronchial mucosa is 
believed to be the controlling factor for its systemic 
absorption. Budesonide and 17-BMP have approxi- 
mately the same water solubility and both are more 
water soluble than BDP (3). The 22R epimer of budes- 
onide is less water soluble than the 22s epimer (4,5). 


















FIG. 1. Chemical structures and primary metabolic pathways of BDP and budesonide. 
However, although budesonide diffuses into the plasma, 
the appearance of 17-BMP in plasma is lim ited by the 
rate of hydrolysis of BDP, which in turn is dependent 
on its speed of dissolution. BDP may therefore form a 
reservoir in the lung which can be converted locally to 
the highly active 17-BMP. Similarly, the formation of 
fatty acid esters of budesonide in the lung, which can be 
readily hydrolysed, may provide for maintenance of the 
active substance in pulmonary tissues (6). 
One disadvantage of the poor water solubility of 
BDP is that the dosage that can be formulated for a 
nebulizer is lower than that for budesonide (50 pg m l-1 
suspension vs. 250 pg m l-* suspension, respectively) (1). 
However, the use of nebulizers has been declining 
because it has been discovered that a metered dose 
inhaler (MDI) plus a spacer device, with or without a 
mask attachment, is a more efficient delivery device 
(see below) and can be substituted for a nebulizer in 
most situations (7-9). 
Pharmacokinetic Properties 
ABSORPTION AND DISTRIBUTION 
The majority of the dose of a corticosteroid adminis- 
tered by inhalation does not reach the desired target 
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TABLE 1. Relative receptor affinities (compared with dexamethasone) of beclometha- 
sone dipropionate, and its metabolites, and budesonide at the glucocorticoid receptor. 
Data from Ref. 3 
Compound Relative receptor affinitya 
Dexamethasone 100 
BDP 43 
17-Beclomethasone monopropionate (17-BMP) 1345 





aThe higher the number the greater the affinity for the glucocorticoid receptor. 
site of the lungs, the actual percentage varying 
between about 10% and 20% depending on the 
delivery device used. No hydrolysis or degradation of 
BDP was observed in artificial gastric juice over a 3 h 
period (lo), whereas rapid hydrolysis to 17-BMP 
occurred in artificial intestinal fluid. This suggests that 
swallowed BDP probably passes through the stomach 
unchanged but is then almost completely hydrolysed 
to 17-BMP in the intestine, epithelial cells, blood or 
liver. Therefore, it is likely that the majority of BDP 
that is ingested enters the systemic circulation as 
17-BMP, with only small amounts of BDP being 
absorbed. It has been estimated that 70% of BDP that 
has been ingested is subject to pre-systemic metabo- 
lism (11). Large variations have been reported in 
the time to maximum plasma concentration (T,,,) 
of BDP following inhalation. In 12 healthy male 
volunteers receiving BDP 2000 ug by inhalation, peak 
plasma concentrations of BDP (1275 pg ml-i) and 
17-BMP (1364 pg ml-i) were observed within 5 min 
and 3 h, respectively (12). In 23 patients with mild 
asthma inhaling BDP 400 ltg formulated with a chlo- 
rofluorocarbon (CFC) propellant or BDP 200 pg with 
a CFC-free propellent, T,,, occurred in 120 min and 
36 min, respectively, with similar peak plasma concen- 
trations being achieved (41 VS. 34 pg ml-*) (13,14). 
Of the budesonide that is ingested, between 10% and 
13% is bioavailable, with approximately 90% subject 
to pre-systemic metabolism (4). The pharmacokinetic 
profiles of the two epimers are broadly similar (4,5). 
Following inhalation, peak plasma concentrations 
of budesonide are achieved within 1 h (4). Systemic 
budesonide is 88% plasma protein bound (4) and has 
a large volume of distribution, approximately 300 1 
(4,5,15). 22R-budesonide has a larger volume of dis- 
tribution than the 22s epimer (424 1 and 245 1, 
respectively), because it is more lipophilic (4,5). 
Similar volumes of distribution for budesonide have 
been found in children with asthma, 4.8 1 kg-l for the 
22R epimer compared with 3.1 1 kg-1 for the 22s 
epimer (16). After inhalation of a single dose of budes- 
onide 1600 pg, the average concentration of the steroid 
in the lung tissue of 11 patients undergoing thora- 
cotomy 1.5-4 h later was 2386 pg ml-i (17,18). The cor- 
responding plasma concentration was 27 1 pg ml-i. 
METABOLISM AND ELIMINATION 
Both BDP and budesonide are inactivated predomi- 
nantly by the liver. BDP is hydrolysed to 17-BMP and 
21-BMP, in the lung and the liver. Wurthwein and 
Rohdewald (10) showed that BDP is transformed only 
slowly and incompletely to 17-BMP when incubated 
with bronchial secretions in vitro. However, when incu- 
bated with human lung tissue, BDP was rapidly 
hydrolysed (half-life 10 min) to 17-BMP. This suggests 
that hydrolysis of BDP commences at first contact 
with the bronchial secretions but occurs considerably 
faster in the presence of esterases following absorption 
into lung cells. 17-BMP is highly stable in lung tissue 
(half-life 12 h). Once in the plasma, there is some inac- 
tivation of 17-BMP by ester interchange to 21-BMP 
However, this is slow compared with the metabolic 
activity of human liver. Andersson and Ryrfeldt (19) 
found that BDP was immediately hydrolysed to BMP 
(both 17- and 21-BMP) in the liver, which was either 
hydrolysed to beclomethasone or biotransformed by 
oxidative and reductive pathways to unknown inactive 
metabolites with short half-lives of 15-30 min. These 
metabolites are excreted either into the bile or in the 
faeces. Jenner and Kirkham (20) have shown that the 
plasma elimination half-lives of BDP and 17-BMP are 
30 and 37 min, respectively, after intravenous adminis- 
tration of 1 mg of radiolabelled BDP In contrast, in 
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TABLE 2. Pharmacokinetic parameters of budesonide, beclomethasone dipropionate (BDP) and 
its active metabolite 17-beclomethasone monopropionate (17-BMP). Data from Refs 3-5,11,12,19 
Oral bioavailability 
Volume of distribution 
Plasma clearance 
Half-life after IV administration 
Budesonide BDP 
- 10% -30% 
301 1 NA 
84 1 h-1 NA 






IV, intravenous; NA, not available. 
12 volunteers, Falcoz et al. (12) reported mean plasma 
elimination half-lives of 6 min and 6.5 h for BDP and 
17-BMP, respectively, after inhalation of BDP 2000 ug. 
Budesonide, unlike BDP, is not biotransformed in the 
lung or gastrointestinal tract (2). In the liver, budes- 
onide is metabolized primarily via oxidative and, to 
a much lesser extent, reductive pathways to six 
metabolites, primarily 16a-hydroxy-prednisolone and 
b/3-hydroxy-budesonide (21,22). These metabolites are 
the products of the inducible form of cytochrome P450, 
CYP3A4 (18), and have similar half-lives to the parent 
compound but are relatively inactive (50- to 200-fold 
less active than budesonide) (4). Hepatic metabolism of 
budesonide occurs 24 times faster than that of either 
17-BMP or 21-BMP (4,19). Total plasma clearance of 
unchanged budesonide is 84 1 h-1 and is 117 and 68 1 h-1 
for the 22R and 22s epimers, respectively (4). 
As mentioned earlier, it is desirable that an inhaled 
corticosteroid has a short half-life in plasma. The half- 
life of unchanged budesonide following both inhalation 
and intravenous administration to healthy volunteers 
has been reported to be between 2 and 3 h (4). 
The important pharmacokinetic parameters of 
BDP and its active metabolite 17-BMP, and of budes- 
onide are summarized in Table 2. 
Delivery Devices 
The method by which an inhaled medication is 
delivered will obviously influence its lung deposition 
characteristics. Selroos et al. (23) have performed 
a comprehensive comparison of delivery devices 
(excluding nebulizers) for inhaled asthma medication. 
At present, the MD1 is the most widely used device. 
Typically, 10-l 5% of a dose from an MD1 is deposited 
in the lungs. The use of a spacer device attached to an 
MD1 approximately doubles the percentage of drug 
reaching the lungs. Drug deposition from a dry pow- 
der inhaler is similar to that from an MD1 whereas 
delivery from a breath-actuated device is between 20% 
and 35%, depending on the drug. Deposition from the 
newer CFC-free MDIs containing BDP appears to be 
substantially greater than that from the conventional 
BDP MD1 (13,24). With a nebulizer, only approxi- 
mately 10% of the total dose reaches the lungs, with 
the majority of the drug being lost in the apparatus, to 
the air, or exhaled (25). 
The higher the percentage of the total drug dosage 
that reaches the lungs, the greater the local clinical effi- 
cacy. At the same time, the lower the percentage of 
extrapulmonary deposition, the lower the risk of 
oropharyngeal and, possibly, systemic adverse effects, 
Inter- and intraindividual differences in device tech- 
nique can also have an impact on drug deposition. 
The various delivery devices also differ regarding 
their ease of use, portability, association with local 
adverse effects (such as inhaler-induced cough) and 
cost, and all of these factors should be considered in 
combination with the patient’s requirements when 
inhaled corticosteroid therapy is initiated (26,27). 
Efforts must be made to ensure that the patient is 
capable of correctly and consistently performing all 
steps associated with proper use of the particular 
device, and technique should be reassessed periodically 
(28). Pedersen (27) has reviewed the advantages and 
limitations of the various delivery devices. A nebulizer 
is the appropriate device for children ~6 months of age 
(28,29). It should be possible to use an MD1 plus 
spacer with a fitted infant facemask for children aged 
between 6 months and 1 year. An MD1 plus spacer 
with mask is suitable for children aged l-5 years 
(27,28). Children aged >5 years are often able to use a 
dry powder inhaler; those aged >7 years should be 
able to use a breath-actuated device or an MD1 plus 
spacer without a mask (27). An MD1 plus spacer, 
breath-actuated device or dry powder device is prefer- 
able for elderly or other individuals who have difficulty 
co-ordinating inspiration and device actuation. The 
area of delivery devices will continue to evolve as new 
CFC-free inhalers are introduced over the next few 
years and new spacer devices are developed. 
Additional research comparing the different types of 
delivery devices is required, as are studies determining 
which devices are most suitable for which patients. 
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Summary 
The physicochemical and pharmacokinetic character- 
istics of BDP and budesonide are somewhat different, 
but the overall result is that both are well suited for use 
as inhaled corticosteroids. Both BDP and budesonide 
are metabolized primarily by the liver, with one of 
the metabolites of BDP, 17-BMP, having greater 
receptor affinity than either the parent compound 
or budesonide, which has no active metabolites. BDP 
has a lower water solubility than either 17-BMP or 
budesonide, which have similar water solubilities. 
Budesonide has lower oral bioavailability than BDP; 
however, it is generally reported to have a longer 
plasma half-life than either BDP or 17-BMP The 
physicochemical and pharmacokinetic profiles of 
inhaled BDP and budesonide provide both compounds 
with a favourable ratio of topical to systemic effects 
and support their well-established role in the treatment 
of asthma. The device used to deliver an inhaled corti- 
costeroid influences the lung deposition of the drug 
and selection of the device should be made with an 
understanding of the particular advantages and disad- 
vantages of the device for each individual patient. 
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